EMEA-000069-PIP02-10-M08

Key facts

Invented name
Nucala
Active substance
Mepolizumab
Therapeutic area
Pneumology-allergology
Decision number
P/0239/2017
PIP number
EMEA-000069-PIP02-10-M08
Pharmaceutical form(s)
  • Powder for solution for injection / infusion
  • Solution for injection
Condition(s) / indication(s)
Treatment of asthma
Route(s) of administration
  • Intravenous use
  • Subcutaneous use
Contact for public enquiries
GlaxoSmithKline Trading Services
United Kingdom
Tel . +44 (0)20 8990 3650
E-mail: eu.paediatric-plans@gsk.com
Decision type
PM: decision on the application for modification of an agreed PIP
Compliance procedure number
EMEA-C-000069-PIP02-10-M08
Compliance opinion date
10/11/2017
Compliance outcome
positive

Decision

How useful was this page?

Add your rating